Evidence map›Paper›PMID 39896289›Full record

ReviewMaterials today. Bio2025

Utilization of nanotechnology to surmount the blood-brain barrier in disorders of the central nervous system.

Qian Luo, Jiaying Yang, Mei Yang, Yingtong Wang, Yiran Liu, Jixuan Liu, Dhan V Kalvakolanu, Xianling Cong, Jinnan Zhang, Ling Zhang and 2 more

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Materials today. Bio, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Review
  9. Review
  10. Sprouty in Tumors of the Nervous System.International journal of molecular sciences · 2025
    Review
  11. Review
  12. Review
  13. Review
  14. Article
  15. Review
  16. Review
  17. Review
  18. Review
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Qian LuoDepartment of Plastic Surgery, China-Japan Union Hospital, Jilin University, Changchun, 130033, China.
Jiaying YangKey Laboratory of Pathobiology, Ministry of Education, And Department of Biomedical Science, College of Basic Medical Sciences, Jilin University, Changchun, 130021, China.
Mei YangKey Laboratory of Pathobiology, Ministry of Education, And Department of Biomedical Science, College of Basic Medical Sciences, Jilin University, Changchun, 130021, China.
Yingtong WangThe Undergraduate Center of Hospital of Stomatology, Jilin University, Changchun, 130021, China.
Yiran LiuDepartment of Plastic Surgery, China-Japan Union Hospital, Jilin University, Changchun, 130033, China.
Jixuan LiuKey Laboratory of Pathobiology, Ministry of Education, And Department of Biomedical Science, College of Basic Medical Sciences, Jilin University, Changchun, 130021, China.
Dhan V KalvakolanuGreenebaum NCI Comprehensive Cancer Center, Department of Microbiology and Immunology University of Maryland School Medicine, Baltimore, MD, USA.
Xianling CongDepartment of Plastic Surgery, China-Japan Union Hospital, Jilin University, Changchun, 130033, China.
Jinnan ZhangDepartment of Plastic Surgery, China-Japan Union Hospital, Jilin University, Changchun, 130033, China.
Ling ZhangKey Laboratory of Pathobiology, Ministry of Education, And Department of Biomedical Science, College of Basic Medical Sciences, Jilin University, Changchun, 130021, China.
Baofeng GuoDepartment of Plastic Surgery, China-Japan Union Hospital, Jilin University, Changchun, 130033, China.
Yanhong DuoJohn A. Paulson School of Engineering and Applied Sciences, Harvard University, Cambridge, MA, 02138, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Central nervous system (CNS) diseases are a major cause of disability and death worldwide. Due to the blood-brain barrier (BBB), drug delivery for CNS diseases is extremely challenging. Nano-delivery systems can overcome the limitations of BBB to deliver drugs to the CNS, improve the ability of drugs to target the brain and provide potential therapeutic methods for CNS diseases. At the same time, the choice of different drug delivery methods (bypassing BBB or crossing BBB) can further optimize the therapeutic effect of the nano-drug delivery system. This article reviews the different methods of nano-delivery systems to overcome the way BBB enters the brain. Different kinds of nanoparticles to overcome BBB were discussed in depth.

Indexed as

Cerebrovascular barrierDisorders of the central nervous systemNanoscale delivery platformsNano-sized particles

Identifiers

PMID39896289
PMCPMC11786670

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.